title: Management after first-line antiresorptive treatment for postmenopausal osteoporosis.
authors.affiliation: Rheumatology, Hôpital Roger-Salengro, CHRU de Lille, rue Émile-Laine, 59037 Lille, France. Electronic address: julienpaccou@yahoo.fr.
authors.forename: Julien
authors.initials: J
authors.lastname: Paccou
mesh_terms: D015502:Absorptiometry, Photon / Q000379:methods; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000069448:Denosumab / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D000069448:Denosumab; D019386:Alendronate
keywords: Bisphosphonates; Denosumab; Fractures; Osteoporosis; T-score